Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015


  • Products Id :- GDHC2566CTIDB
  • |
  • Pages: 79
  • |
  • |
  • |
  Request for Sample Report
  Request A Quote

Executive Summary

Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015

GlobalData's clinical trial report, "Non-Rhabdomyosarcoma Global Clinical Trials Review, H1, 2015" provides data on the Non-Rhabdomyosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Rhabdomyosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Non-Rhabdomyosarcoma. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each

Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type

Listings of discontinued trials (suspended, withdrawn and terminated)

Reasons To Buy

Understand the dynamics of a particular indication in a condensed manner

Abridged view of the performance of the trials in terms of their status, recruitment, location, sponsor type and many more

Obtain discontinued trial listing for trials across the globe

Espy the commercial landscape of the major Universities / Institutes / Hospitals or Companies



Read More



Contact Us:
Ken Research
Ankur Gupta, Head Marketing & Communications

+91-9015378249

Table of Contents

Table of Contents 2

List of Tables 4

List of Figures 5

Introduction 6

Non-Rhabdomyosarcoma 6

Report Guidance 6

Clinical Trials by Region 7

Clinical Trials and Average Enrollment by Country 8

Top Five Countries Contributing to Clinical Trials in Asia-Pacific 10

Top Five Countries Contributing to Clinical Trials in Europe 11

Top Countries Contributing to Clinical Trials in North America 12

Top Countries Contributing to Clinical Trials in Middle East and Africa 13

Top Countries Contributing to Clinical Trials in Central and South America 14

Clinical Trials by G7 Countries: Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials 15

Clinical Trials by Phase in G7 Countries 16

Clinical Trials in G7 Countries by Trial Status 17

Clinical Trials by E7 Countries: Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials 18

Clinical Trials by Phase in E7 Countries 19

Clinical Trials in E7 Countries by Trial Status 20

Clinical Trials by Phase 21

In Progress Trials by Phase 22

Clinical Trials by Trial Status 23

Clinical Trials by End Point Status 24

Unaccomplished Trials of Non-Rhabdomyosarcoma 25

Subjects Recruited Over a Period of Time 28

Clinical Trials by Sponsor Type 29

Prominent Sponsors 30

Top Companies Participating in Non-Rhabdomyosarcoma Therapeutics Clinical Trials 31

Prominent Drugs 32

Clinical Trial Profiles 33

Clinical Trial Overview of Top Companies 33

Pfizer Inc. 33

Clinical Trial Overview of Pfizer Inc. 33

Zeltia, S.A. 34

Clinical Trial Overview of Zeltia, S.A. 34

GlaxoSmithKline plc 35

Clinical Trial Overview of GlaxoSmithKline plc 35

Johnson & Johnson 36

Clinical Trial Overview of Johnson & Johnson 36

F. Hoffmann-La Roche Ltd. 37

Clinical Trial Overview of F. Hoffmann-La Roche Ltd. 37

Novartis AG 38

Clinical Trial Overview of Novartis AG 38

Merck & Co., Inc. 39

Clinical Trial Overview of Merck & Co., Inc. 39

Daiichi Sankyo Company, Limited 40

Clinical Trial Overview of Daiichi Sankyo Company, Limited 40

Clinical Trial Overview of Top Institutes / Government 41

National Cancer Institute 41

Clinical Trial Overview of National Cancer Institute 41

European Organization for Research and Treatment of Cancer 42

Clinical Trial Overview of European Organization for Research and Treatment of Cancer 42

Children's Oncology Group 43

Clinical Trial Overview of Children's Oncology Group 43

Memorial Sloan Kettering Cancer Center 44

Clinical Trial Overview of Memorial Sloan Kettering Cancer Center 44

Fred Hutchinson Cancer Research Center 45

Clinical Trial Overview of Fred Hutchinson Cancer Research Center 45

University of Heidelberg 46

Clinical Trial Overview of University of Heidelberg 46

Massachusetts General Hospital 47

Clinical Trial Overview of Massachusetts General Hospital 47

Institut Bergonie 48

Clinical Trial Overview of Institut Bergonie 48

Five Key Clinical Profiles 49

Appendix 77

Abbreviations 77

Definitions 77

Research Methodology 78

Secondary Research 78

About GlobalData 79

Contact Us 79

Disclaimer 79

Source 79

List of Figures

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region (%), 2015* 7

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries (%), 2015* 10

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries (%), 2015* 11

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries (%), 2015* 12

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries (%), 2015* 13

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries (%), 2015* 14

Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase (%), 2015* 21

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase, 2015* 22

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Non-Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type (%), 2015* 29

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

GlobalData Methodology 78

List of Tables

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Region, 2015* 7

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials and Average Enrollment by Top Countries, 2015* 8

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Top Countries, 2015* 9

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Asia-Pacific, Top Five Countries, 2015* 10

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Europe, Top Five Countries, 2015* 11

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, North America, Top Countries, 2015* 12

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Middle East and Africa, Top Countries, 2015* 13

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Central and South America, Top Countries, 2015* 14

Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, G7 Countries (%), 2015* 15

Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Phase, 2015* 16

Non-Rhabdomyosarcoma Therapeutics, G7 Countries, Clinical Trials by Trial Status, 2015* 17

Proportion of Non-Rhabdomyosarcoma to Oncology Clinical Trials, E7 Countries (%), 2015* 18

Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Phase, 2015* 19

Non-Rhabdomyosarcoma Therapeutics, E7 Countries, Clinical Trials by Trial Status, 2015* 20

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Phase, 2015* 21

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials In Progress by Phase 2015* 22

Non-Rhabdomyosarcoma Therapeutics, Global, Clinical Trials by Trial Status, 2015* 23

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, by End Point Status, 2015* 24

Non-Rhabdomyosarcoma Therapeutics, Global, Suspended Clinical Trials, 2015* 25

Non-Rhabdomyosarcoma Therapeutics, Global, Withdrawn Clinical Trials, 2015* 26

Non-Rhabdomyosarcoma Therapeutics, Global, Terminated Clinical Trials, 2015* 27

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Average Enrollment Target Trends, 2010-2014 28

Non-Rhabdomyosarcoma Therapeutics Market, Global, Clinical Trials by Sponsor Type, 2015* 29

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Key Sponsors, 2015* 30

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Top Companies by Phase, 2015* 31

Non-Rhabdomyosarcoma Therapeutics Clinical Trials, Global, Ongoing Clinical Trials by Prominent Drugs, 2015* 32

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Pfizer Inc., 2015* 33

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Zeltia, S.A., 2015* 34

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by GlaxoSmithKline plc, 2015* 35

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Johnson & Johnson, 2015* 36

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by F. Hoffmann-La Roche Ltd., 2015* 37

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Novartis AG, 2015* 38

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Merck & Co., Inc., 2015* 39

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Daiichi Sankyo Company, Limited, 2015* 40

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by National Cancer Institute, 2015* 41

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by European Organization for Research and Treatment of Cancer, 2015* 42

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Children's Oncology Group, 2015* 43

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Memorial Sloan Kettering Cancer Center, 2015* 44

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Fred Hutchinson Cancer Research Center, 2015* 45

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by University of Heidelberg, 2015* 46

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Massachusetts General Hospital, 2015* 47

Non-Rhabdomyosarcoma Therapeutics Clinical Trials Market, Global, Clinical Trials by Institut Bergonie, 2015* 48

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to query [@] kenresearch.com
 

Non-Rhabdomyosarcoma Clinical Trials, Trial Designs, Subjects Recruited, Unaccomplished Trials of Non-Rhabdomyosarcoma, Pfizer, AstraZeneca, Novartis, GlaxoSmithKline, Sanofi, Eli Lilly and Company, Johnson & Johnson, Merck & Co., Inc, Bristol-Myers Squibb Company, Abbott Laboratories, Hoffmann-La Roche Ltd., Celgene Corporation, Daiichi Sankyo Company, Ltd., Bayer AG, Eisai Inc., GE Healthcare, Biogen Idec Inc., Copharos Inc., Wyeth Pharmaceuticals Inc., National Cancer Center, The University of Texas, M.D. Andersons, Vanderbilt Medical Center, Memorial Sloan Kettering Cancer Center, Cancer Research UK, North Central Cancer Group, Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Fred Hutchinson Cancer Research Center, European Organization for Research and Treatment of Cancer, Dana-Farber Cancer Institute, The Cancer and Leukemia Group B, Columbia University, UCLA's Jonsson Comprehensive Cancer Center, Case Comprehensive Cancer Center, Mayo Clinic, Duke University, Ohio State University, National Cancer Center, University of Pennsylvania.

select a license

Single User License
USD 2500 INR 162350
Site License
USD 5000 INR 324700
Corporate User License
USD 7500 INR 487050

NEWSLETTER BY CATEGORY




Testimonials

The report sent to us was on the point, and its information was quite extensive, well structured, and well researched. More importantly what we valued was your response time and professionalism. As a leading global consulting firm, our clients expect high quality deliverables in short periods of time, so a reliable research partner is essential. For the price that you have charged the quality of your services were exceptional. We look forward to continue our relationship with your team on future engagements....

This is with regards to your report on India PVC pipes and fitting market outlook industry outlook to 2019. This is a very well written report and accept my compliments on the same.... ...

I am pleased to see the very useful and productive information in the report..Very well structured great presentation reflect professionalism in your research studies....

While we still are studying and analysing your reports about Vietnam & Thailand, we would like to convey to your research team that they have done a very good job in compiling so much of information together. We hope to see more of such well researched reports. All the best & keep it up. ...

We would like to appreciate Ken Research for their great efforts and wonderful support in providing the Market Intelligence Report for ITPC. The information, statistics and research are well understandable and very clear to the point. We are happy with Ken research for their good client service, on-time delivery of the report and as said the report itself. Thank you Ken research for bringing the valuable output for us. We would be looking forward to have more research with you in the near future. Wish you a success in your business!...



Related Products in vertical
Ken Research Pvt. Ltd. Unit 14, Tower B3, Spaze I Tech Business Park, Sohna Road, sector 49
     Gurgaon, Haryana - 122001, India

download

Company Brochure

Engage with Us

query [@] kenresearch.com